Skip Navigation

U.S. Flag

Print Print   Download Reader Download   Text Enlarge text size Reduce text size Normal text size

Go to Text Version

HHS Recovery Act Recipient Reporting Readiness Tool

Step 4. Review and Copy the Grant Awards Data

TAGGS provides some – but not all – of the data needed for the Recipient Report. Recipients are responsible for directly collecting and reporting all required data to FederalReporting.gov. Data that HHS does not currently collect are highlighted in yellow. Do not copy this highlighted information. Please enter the appropriate data for your organization in these required fields. For assistance with entering these data please contact FederalReporting.gov.

You may capture the data HHS does provide by copying data from this screen and pasting it into the reporting format of your choice, such as the Excel spreadsheet template, the XML template, or by logging into the online form. For assistance with copying and pasting these data please e-mail our help desk at Readiness Help.

 

Award Detail for: ISOLATION AND CHARACTERIZATION OF PROSTRATE ANTIGEN SPECIFIC HIGH AFFINITY TCR
MEDICAL UNIVERSITY OF SOUTH CAROLINA
DUNS Number: 183710748
19 HAGOOD AVE, SUITE 608
CHARLESTON, SC 29403-5120
Recipient Report: Grant or Loan
Prime Recipient

Reporting Information
Award Type Award Number Final Report
Grant 1R21CA137725-01 Recipient responsible for this data

Award Recipient Information
Recipient DUNS Number Recipient Account Number Recipient Congressional District
183710748 Recipient responsible for this data 1

Award Information
Funding Agency Code Awarding Agency Code Award Date
7529 7529 05-18-2009
Amount of Award Sub Account Number for Program Source (TAS)  
$ 162,250 Recipient responsible for this data
Program Source (TAS)* CFDA Number 
750850 93.701
Total Number of Sub Awards to Individuals Total Amount of Sub Awards to Individuals
Recipient responsible for this data Recipient responsible for this data
Total Number of Payments to Vendors less than $25,000/award Total Amount of Payments to Vendors less than $25,000/award
Recipient responsible for this data Recipient responsible for this data
Total Number of Sub Awards less than $25,000/award Total Amount of Sub Awards less than $25,000/award
Recipient responsible for this data Recipient responsible for this data
Award Description
DESCRIPTION (provided by applicant): A key factor that has so far limited the efficacy of immunotherapy for prostate cancer patients is the poor immunogenicity of TAA expressed by prostate cancer cells. This poor immunogenicity is likely due to immunologic tolerance to antigens expressed by normal cells of the prostate. As a result, the development of therapeutic vaccines and adoptive T cell transfer approaches for treating prostate cancer has made little progress over the years. The studies outlined in this application take advantage of a gene therapy approach that is capable of redirecting the specificity of normal peripheral blood T cells to recognize tumor cells. We will take advantage of the fact that the antigenic peptides expressed by prostate cancer cells that are targeted by our T cells need not be immunogenic in prostate cancer patients since we would be providing them their own T cells engineered to recognize their tumors. Given that women lack prostate glands, their T cells should not be tolerant to prostate cancer antigens. Furthermore, their T cells may express T cell receptors with higher affinity for prostate cancer antigens than similar T cells in men. Therefore, this application proposes to isolate prostate cancer reactive T cell clones from the PBL of women. We will then identify and clone the T cell receptors from these prostate cancer reactive T cells and construct retroviral vectors capable of engineering normal PBL-derived T cells to recognize prostate cancer cells. We will then evaluate these TCR transduced T cells for their efficacy in vitro and in vivo. While this application applies existing technologies and established immunologic concepts to the development of new treatments for prostate cancer patients, we believe the unorthodox source of T cells adds a novel twist to this study. In addition to the potential for a new treatment option for prostate cancer patients, this study will increase our understanding of tolerance to prostate cancer antigens that may assist those in developing new prostate cancer vaccines. PUBLIC HEALTH RELEVANCE: This proposal is to isolate T cell clones bearing high affinity T cells receptors (TCR) reactive with prostate specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA) and to characterize their efficacy after engineering them on normal peripheral blood T cells to recognize prostate cancer cells. The strength of our proposal is its innovative hypothesis that prostate antigen reactive T cells isolated from normal adult females would have higher avidity and express higher affinity TCRs than similar T cells isolated from males. On successful completion of this project we hope to circumvent immunologic tolerance in patients with local and advanced prostate cancer by providing them with their own T cells engineered with high affinity TCR to recognize and kill their tumors.

Project Information
Project Name or
Project/Program Title
Project Status Total Federal Amount ARRA Funds
Received/Invoiced
ISOLATION AND CHARACTERIZATION OF PROSTRATE ANTIGEN SPECIFIC HIGH AFFINITY TCR Recipient responsible for this data Recipient responsible for this data
Number of Jobs Description of Jobs Created
Recipient responsible for this data Recipient responsible for this data
Quarterly Activities/Project Description
Recipient responsible for this data
 
Activity Code (NAICS or NTEE-NPC)
1Recipient responsible for this data2Recipient responsible for this data
3Recipient responsible for this data4Recipient responsible for this data
5Recipient responsible for this data6Recipient responsible for this data
7Recipient responsible for this data8Recipient responsible for this data
9Recipient responsible for this data10Recipient responsible for this data
Total Federal Amount of ARRA
Expenditure
Total Federal ARRA
Infrastructure Expenditure
Infrastructure Contact Name
Recipient responsible for this data Recipient responsible for this data Recipient responsible for this data
Infrastructure Contact Email Infrastructure Contact Phone Infrastructure Contact Phone Ext.
Recipient responsible for this data Recipient responsible for this data Recipient responsible for this data
Infrastructure Contact Street Address 1 Infrastructure Contact Street Address 2 Infrastructure Contact Street Address 3
19 HAGOOD AVE, SUITE 608 Not Available Recipient responsible for this data
Infrastructure City Infrastructure State Infrastructure ZIP Code+4
CHARLESTON SC 29403-5120
Infrastructure Purpose and Rationale
Recipient responsible for this data

Primary Place of Performance
Street Address 1 Street Address 2 City
19 HAGOOD AVE., SUITE 606MSC 808 Recipient responsible for this data CHARLESTON
State Zip Code+4 Congressional District
SC 29425 1
Country  
US

Recipient Highly Compensated Officers
Prime Recipient Indication of Reporting Applicability # Officer Name Officer Compensation
Recipient responsible for this data 1 Recipient responsible for this data Recipient responsible for this data
2 Recipient responsible for this data Recipient responsible for this data
3 Recipient responsible for this data Recipient responsible for this data
4 Recipient responsible for this data Recipient responsible for this data
5 Recipient responsible for this data Recipient responsible for this data

This concludes the current search.
To begin a new search, return to the HHS Recovery Act Recipient Reporting Readiness Tool.

USE IN THE RECIPIENT REPORT

The information provided by this tool is baseline data that the Recipient should include in the Recipient Report that must be submitted to FederalReporting.gov beginning October 1, 2009. The data from this tool can be cut and pasted directly into the Recipient Report.